Identification

Name
Gaboxadol
Accession Number
DB06554
Description

Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing effects of benzodiazepines. Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 140.1399
Monoisotopic: 140.05857751
Chemical Formula
C6H8N2O2
Synonyms
  • 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
  • THIP
External IDs
  • LU-02-030
  • MK-0928

Pharmacology

Indication

Investigated for use/treatment in sleep disorders and insomnia.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Gaboxadol.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Gaboxadol.
AclidiniumGaboxadol may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Gaboxadol.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Gaboxadol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Gaboxadol.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Gaboxadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gaboxadol.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Gaboxadol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Isoxazoles / Heteroaromatic compounds / Oxacyclic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Isoxazole / Organic oxygen compound / Organoheterocyclic compound / Organooxygen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
oxazole (CHEBI:34373)

Chemical Identifiers

UNII
K1M5RVL18S
CAS number
64603-91-4
InChI Key
ZXRVKCBLGJOCEE-UHFFFAOYSA-N
InChI
InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
IUPAC Name
2H,3H,4H,5H,6H,7H-[1,2]oxazolo[5,4-c]pyridin-3-one
SMILES
O=C1NOC2=C1CCNC2

References

General References
Not Available
KEGG Drug
D04282
KEGG Compound
C13693
PubChem Compound
3448
PubChem Substance
175427072
ChemSpider
3330
BindingDB
82002
ChEBI
34373
ChEMBL
CHEMBL312443
ZINC
ZINC000019795995
Wikipedia
Gaboxadol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentPrimary Disease or Condition Being Studied: Angelman Syndrome (AS)1
3CompletedTreatmentInsomnia4
3CompletedTreatmentPrimary Insomnia6
3TerminatedTreatmentPrimary Insomnia2
3WithdrawnTreatmentInsomnia1
2CompletedTreatmentAngelman's syndrome1
2CompletedTreatmentFragile X Syndrome (FXS)1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentPrimary Insomnia1
2RecruitingTreatmentAngelman's syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility16.6 mg/mLALOGPS
logP-1.3ALOGPS
logP-2ChemAxon
logS-0.93ALOGPS
pKa (Strongest Acidic)5.12ChemAxon
pKa (Strongest Basic)8.85ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.36 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity35.5 m3·mol-1ChemAxon
Polarizability13.31 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
L-proline transmembrane transporter activity
Specific Function
Neutral amino acid/proton symporter. Has a pH-dependent electrogenic transport activity for small amino acids such as glycine, alanine and proline. Besides small apolar L-amino acids, it also recog...
Gene Name
SLC36A1
Uniprot ID
Q7Z2H8
Uniprot Name
Proton-coupled amino acid transporter 1
Molecular Weight
53075.045 Da
References
  1. Larsen M, Holm R, Jensen KG, Sveigaard C, Brodin B, Nielsen CU: 5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. Eur J Pharm Sci. 2010 Jan 31;39(1-3):68-75. doi: 10.1016/j.ejps.2009.10.013. Epub 2009 Nov 10. [PubMed:19900542]

Drug created on March 19, 2008 10:36 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates